Targeting macrophages is the key to expanding the potential of immunotherapy.

At Verseau, we are developing novel, first-in-class immunotherapies that modulate macrophages to provide greater clinical benefit over existing treatments.

Macrophages are the master orchestrators of the immune system. Verseau has identified and validated numerous macrophage-related targets that modulate the immune response by either activating anti-tumor immunity or silencing exaggerated activity. These proprietary macrophage checkpoint modulators have been shown to generate a coordinated and powerful immune response with therapeutic potential in both oncology and inflammatory diseases.

Current immunotherapies can only provide clinical benefit in the ~25% of cancers that involve T cell infiltration. By targeting macrophages, which are present in 75% of tumors, Verseau’s macrophage checkpoint modulators can expand the potential clinical benefits of immunotherapy to a large, underserved patient population.

Watch our videos to learn how Verseau is developing innovative treatments for patients.

To see current openings at Verseau and learn about joining our team visit our Careers page.